CD BioGlyco, a leading provider in the field of glycoproteomics, has recently updated its Glycoprotein Quantification Service. This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development.
Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. Changes in glycoprotein abundance and glycan structures are closely linked to various diseases, including genetic disorders, immunodeficiencies, cardiovascular diseases, and cancer.
The updated service from CD BioGlyco contains:
Relative Quantification of Glycoprotein
CD BioGlyco provides relative quantification of glycoprotein at the site-specific glycosylation level/protein level/occupancy level.
Absolute Quantification of Glycoprotein
CD BioGlyco provides absolute quantification of glycans derivatized with reductive amination chemistry/with reagents that introduce a cationic charge…
Leveraging advanced analytical techniques such as fluorescence spectroscopy, capillary electrophoresis, laser-induced fluorescence detection, hydrophilic interaction chromatography, and mass spectrometry, CD BioGlyco’s updated service can sensitively monitor the abundance and structural changes of glycans. The integration of stable isotope labeling further enhances the accuracy and reliability of glycoprotein quantification.
“Our goal is to provide researchers with the best tools and methodologies to explore the intricate world of glycoproteins,” said Anna, one of the representative speakers from CD BioGlyco. “With our updated Glycoprotein Quantification Service, we are confident that our clients will achieve groundbreaking insights into glycoprotein structure and function, aiding in the discovery of important biomarkers and the understanding of disease mechanisms.”
In addition to glycoprotein quantification, CD BioGlyco offers a comprehensive glycoproteomics platform. This platform addresses the challenges posed by the structural diversity of glycans and the heterogeneity of glycosylation sites. The rapid development of mass spectrometry instruments and high-throughput workflows has enabled CD BioGlyco to provide in-depth analysis of glycoproteins, including glycosylation site elucidation and structural characterization.
“CD BioGlyco is dedicated to advancing glycobiology research,” Anna added. “Our updated services are a testament to our dedication to quality and efficiency. We look forward to collaborating with scientists and researchers, helping them push the boundaries of what is possible in glycoproteomics.”
For more information about CD BioGlyco’s updated Glycoprotein Quantification Service and other offerings, please visit https://www.bioglyco.com/glycoprotein-quantification.html.
